TGFB1 and neoplasm: have shown that treating allogeneic NK cells with integrins or TGF-β signaling inhibitors, or engineering TGFBR2 gene-edited allogeneic NK cells, can prevent GSC-induced NK cell dysfunction and tumor growth in mice transplanted with GSCs.